Overexpression of the NLRP3 inflammasome has been attributed
to
the progressive worsening of a multitude of cardiovascular inflammatory
diseases such as myocardial infarction, pulmonary arterial hypertension,
and atherosclerosis. The recently discovered potent and selective
NLRP3 inhibitor MCC950 has shown promise in hindering disease progression,
but NLRP3-selective cardiovascular positron emission tomography (PET)
imaging has not yet been demonstrated. We synthesized [11C]MCC950 with no-carrier-added [11C]CO2 fixation
chemistry using an iminophosphorane precursor (RCY 45 ± 4%, >99%
RCP, 27 ± 2 GBq/μmol, 23 ± 3 min, n = 6) and determined its distribution both in vivo and ex vivo in C57BL/6 and atherogenic ApoE
–/– mice. Small animal PET
imaging was performed in both strains following intravenous administration
via the lateral tail vein and revealed considerable uptake in the
liver that stabilized by 20 min (7–8.5 SUV), coincident with
secondary renal excretion. Plasma metabolite analysis uncovered excellent in vivo stability of [11C]MCC950 (94% intact). Ex vivo autoradiography performed on excised aortas revealed
heterogeneous uptake in atherosclerotic plaques of ApoE
–/– mice in comparison to C57BL/6 controls
(48 ± 17 %ID/m2 vs 18 ± 8 %ID/m2, p = 0.002, n = 4–5). Treatment of ApoE
–/– mice with nonradioactive
MCC950 (5 mg/kg, iv) 10 min prior to radiotracer administration increased
uptake in the intestine (5.3 ± 1.8 %ID/g vs 11.0 ± 3.7 %ID/g, p = 0.04, n = 4–6) and in aortic
lesions (48 ± 17 %ID/m2 vs 104 ± 15 %ID/m2, p = 0.0002, n = 5) by
108% and 117%, respectively, without significantly increasing plasma
free fraction (f
p, 1.3 ± 0.4% vs
1.7 ± 0.8%, n = 2). These results suggest that
[11C]MCC950 uptake demonstrates specific binding and may
prove useful for in vivo NLRP3 imaging in atherosclerosis.